Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 511-516

  DeNardo, Gerald L ^a,c   Mirick, G R ^a   Hok, S ^b   DeNardo, S J ^a   Beckett, L A ^a   Adamson, G N ^a   Balhorn, R L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^c NONE   (United States)

Author keywords

Antibody; High affinity ligands; HLA DR signaling; Leukemia; Lymphoma; Nanomolecules; Therapy

Indexed keywords

3 [2 [[(3 CHLORO 5 TRIFLUOROMETHYL) 2 PYRIDINYL]OXY]ANILINO] 3 OXOPROPANIONIC ACID; ANTINEOPLASTIC AGENT; HLA DR ANTIGEN; HLA DR10 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; B CELL LYMPHOMA; CANCER REGRESSION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; LEUKEMIA; LEUKEMIA CELL LINE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SURVIVAL TIME; T CELL LYMPHOMA; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULINS; JURKAT CELLS; LEUKEMIA; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HETEROLOGOUS;

EID: 64549121188     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000176     Document Type: Article

References (20)

1. DeNardo GL, Natarajan A, Hok S, Mirick G, DeNardo SJ, Corzett M, et al: Nanomolecular HLA-DR10 antibody mimics; a potent system for molecular targeted therapy and imaging. Bioconjug Chem (In press).
2. Leveille C, Cataigne JG, Charron D and Al-Daccak R: MHC class II isotype-specific signaling complex on human B cells. Eur J Immunol 32: 2282-2289, 2002.
3. Klemm JD, Schreiber SL and Crabtree GR: Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 16: 569-592, 1998.
4. Lane PJ, McConnell FM, Schieven GL, Clark EA and Ledbetter JA: The role of class II molecules in human B cell activation. J Immunol 144: 3684-3692, 1990.
5. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 16: 3246-3256, 1998.
6. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL and Meares CF: Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 43: 26-30, 1996.
7. Rose LM, Deng CT, Scott S, Xiong CY, Lamborn KR, Gumerlock PH, et al: Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 36: 789-797, 1999.
8. Epstein AL, Marder RJ, Winter JN, Stathopoulos E, Chen FM, Parker JW, et al: Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 47: 830-840, 1987.
9. DeNardo GL, Tobin E, Chan K, Bradt BM and DeNardo SJ: Direct anti-lymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and yttrium-90 HLA-DR antibodies. Clin Cancer Res 11: 7075-7079, 2005.
10. Tobin E, DeNardo GL, Zhang N, Epstein AL, Liu C and DeNardo SJ: Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Leuk Lymphoma 48: 944-956, 2007.
11. Zhang N, Khawli LA, Hu P and Epstein AL: Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm 22: 342-356, 2007.
12. Balhorn R, Hok S, Burke P, Lightstone FC, Cosman M, Zemla A, et al: Selective high affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia. Clin Cancer Res 13 (Suppl. 18): S5621-S5628, 2007.
13. DeNardo GL, Natarajan A, Hok S, Perkins J, Cosman M, DeNardo SJ, Lighstone FC, Mirick G, Miers LA, Yuan A, Xiong CY and Balhorn R: Pharmacokinetic characterization in xenografted mice of a series of first generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma. J Nucl Med 48: 1338-1347, 2007.
14. West J, Perkins J, Hok S, Balhorn R, Lightstone FC, Cosman M, et al: Direct antilymphoma activity of novel, first-generation 'antibody mimics' that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm 21: 645-654, 2006.
15. Kuntz ID, Blaney JM, Oatley SJ, Langridge R and Ferrin TE: A geometric approach to macromolecule-ligand interactions. J Mol Biol 161: 269-288, 1982.
16. Desjarlais RL, Sheridan RP, Seibel GL, Dixon JS, Kuntz ID and Venkataraqhavan R: Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J Med Chem 31: 722-729, 1988.
17. DeNardo GL, Kukis DL, Shen S, Mausner LF, Meares CF, Srivastava SC, et al: Efficacy and toxicity of 67Cu-2IT-BATLym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin Cancer Res 3: 71-79, 1997.
18. Tait S, Gunn-Moore F, Collison JM, Huang J, Luberski C, Pedraza L, et al: An oligodendrocyte cell adhesion molecule at the site of assembly of the paranodal axo-glial junction. J Cell Biol 150: 657-666, 2000.
19. SAS Institue, Inc. SAS/STAT Version 9.0. 2004. Cary, NC: SAS Institute.
20. Hok S, Natarajan A, Balhorn R, DeNardo SJ, DeNardo GL and Perkins J: Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia. Bioconjug Chem 18: 912-921, 2007.